Patterns of delays in diagnosis amongst patients with smear-positive pulmonary tuberculosis at a teaching hospital in Turkey  by Okur, E. et al.
infections: antimicrobial susceptibility patterns from the
SENTRY antimicrobial surveillance program (United
States and Canada, 1997). Antimicrob Agent Chemother 1999;
43: 385–389.
RESEARCH NOTE
Patterns of delays in diagnosis amongst
patients with smear-positive pulmonary
tuberculosis at a teaching hospital in
Turkey
E. Okur1, A. Yilmaz2, A. Saygi1, A. Selvi2,
F. Su¨ngu¨n1, E. O¨ztu¨rk1 and G. Dabak1
1Heybeliada Center for Chest Diseases and
Thoracic Surgery and 2SSK Su¨reyyapasa Center
for Chest Diseases and Thoracic Surgery,
Pulmonology, Istanbul, Turkey
ABSTRACT
In total, 151 newly diagnosed patients with
smear-positive pulmonary tuberculosis were
studied. The mean time from the onset of symp-
toms to the ﬁrst visit to a physician was 46.4 days;
the mean referral delay was 28.9 days; the mean
delay in diagnosis was 2.4 days; and the mean
delay in treatment initiation was 0.8 days. There
was a delay in consulting a physician by 49% of
patients. A low index of suspicion for tuberculosis
on the part of the physician and healthcare system
and laboratory delays were the most common
reasons for delays in diagnosis.
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Despite efforts to control tuberculosis, the disease
remains a major health problem worldwide. It is
estimated that the annual number of newly
diagnosed cases increased from 7.5 million in
1990 to 11.9 million in 2005; i.e., a 58.6% increase
during a 15-year period [1]. Among communic-
able diseases, tuberculosis is the second most
common cause of death worldwide [2], with an
estimated 19–43% of the world’s population
infected with Mycobacterium tuberculosis [3].
Spread of M. tuberculosis is predominantly by
patients with pulmonary tuberculosis, and it is
believed that smear-positive cases are more infec-
tious than smear-negative cases [4].
The key components of any tuberculosis control
programme are early diagnosis and prompt insti-
tution of effective therapy. This is especially
important for cases of smear-positive pulmonary
tuberculosis because they are the most important
reservoir for the transmission of infection in a
community [5]. It is estimated that an untreated
patient with smear-positive disease may infect
10–14 individuals annually [6]. Delays in diagno-
sis and treatment result in a prolonged period of
infectivity in the community [5,7], and are a
common problem in both developed and devel-
oping countries [5,7–11]. The present study inves-
tigated patterns and reasons for delays among
patients with smear-positive pulmonary tubercu-
losis in Turkey.
The study was conducted at the Heybeliada
Center for Chest Disease and Thoracic Surgery
(Istanbul, Turkey) between January andMay 2004.
In total, 151 newly diagnosed patients with smear-
positive pulmonary tuberculosiswere studied. The
clinical ﬁles of the patients were analysed and a
questionnaire was completed to obtain data con-
cerning age, gender, educational level, economic
status, presence of index case for tuberculosis,
presence of co-morbidity, and appearance of ﬁrst
symptoms. The various intervals and delays in
diagnosis (Fig. 1)were determined for each patient.
Patient application intervals that exceeded 30 days
were considered to be a patient delay. Referral
intervals that exceeded 2 dayswere regarded as an
institutional delay. Diagnosis intervals that excee-
ded 1 daywere considered to be a delayed diagnosis.
Treatment intervals that exceeded 1 day were
recorded as a delayed treatment [9,10,12]. The chi-
square test, ANOVA test or Student’s t-test were used
to assess differences between groups.
The study population comprised 84 (55.6%)
males and 67 (44.4%) females; the mean age
was 30.4 years (range 14–70 years). The delays
associated with the various stages in diagnosis
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and treatment are summarised in Table 1. The
application interval was <30 days for 77 (51%)
patients, and >30 days for 74 (49%) patients
(a patient delay). Age, gender, educational level,
economic status, marital status, presence or
absence of index case and co-morbidity, and
appearance of ﬁrst symptom had no effect on
the application interval and the patient delay
(p > 0.05). The referral interval was <3 days for
15 (10%) patients, 3–5 days for 44 (29.1%)
patients, and >10 days for 92 (60.9%) patients.
In total, 136 (90%) patients experienced an
institutional delay. The diagnosis interval was
<2 days for 77 (51%) patients, 2–3 days for 47
(31.1%) patients, 3–10 days for 25 (16.6%)
patients, and >10 days for two (1.3%) patients;
thus, 49% of patients experienced delays in
diagnosis. The initiation of treatment interval
was <2 days for 139 (92.1%) patients, 2–10 days
for 11 (7.2%) patients, and >10 days for one
(0.7%) patient; thus, 7.9% of patients experi-
enced delays in treatment.
The mean (median) time from the ﬁrst visit to a
physician to initiation of treatment was 31 (19)
days. This interval was <5 days for 12 (7.9%)
patients. In total, 150 (76.1%) patients experienced
a doctor’s delay. The mean (95% CI) interval from
onset of symptoms to initiation of treatment was
77.3 (67.8–86.8) days. Reasons for delays are
summarised in Table 2. The most common reason
for a patient’s delay was neglect of symptoms by
the patient. A low index of suspicion for tuber-
culosis on the part of the physician was the most
common reason for a doctor’s delay.
The median application interval in this study
of 30 days compares favourably with reported
median application intervals of 1.8 months in
Korea [13], 120 days in Tanzania [11] and 8 weeks
in Nigeria [8], but less favourably with median
application intervals of 17.5 days in Turkey [12]
and 3 weeks in Botswana [14]. The importance of
a patient’s delay was higher in the present study
than in previous reports [9,12]. The median
doctor’s delay of 19 days was short compared
with a median doctor’s delay of 7 weeks in
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Fig. 1. Components of the delay in diagnosis and treatment for patients with pulmonary tuberculosis
Table 1. Values (days) associated with delays in treatment
and diagnosis for patients with pulmonary tuberculosis
Intervals Mean SD Median 95% CI
Application 46.4 54.6 30 37.6–55.1
Referral 28.9 35.1 17 22.5–33.7
Diagnosis 2.4 2.1 1 2.1–2.7
Treatment 0.8 1.3 1 0.6–1
Table 2. Possible reasons for patients’ and doctors’ delays




Neglect of symptoms 32 43.2
Sociocultural factors 15 20.3
Distance to hospital or lack of transport 15 20.3




A low index of suspicion for tuberculosis 77 54.2
Healthcare system 23 16.3
Laboratory system 12 8.5
Distance to hospital 11 7.7
Under-utilised sputum examinations 7 4.9
Economic status 7 4.9
Sociocultural reasons 5 3.5
Total 142 100
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Malaysia [15], 8 weeks in Ghana [5] and 5 weeks
in Botswana [14], but longer than that in other
studies [8,16]. As reported elsewhere [9,12], the
results indicated that the institutional delay was
more signiﬁcant than delays in diagnosis and
treatment. The most common reasons for a
doctor’s delay were a low index of suspicion
for tuberculosis on the part of physicians and
healthcare system, as well as laboratory delays
and the distance to a hospital. Previous studies
have reported similar ﬁndings, and have also
identiﬁed under-utilised chest X-ray examination
facilities and a failure to perform sputum smear
examinations as important reasons for a doctor’s
delay [11,12,14,16,17].
In conclusion, delays in diagnosis and treat-
ment of pulmonary tuberculosis were a common
problem at the Heybeliada Center for Chest
Disease and Thoracic Surgery. Delayed diagnosis
results in a more advanced disease state, the
likelihood of complications, increased mortality,
and enhanced transmission of infection among
healthcare workers and in the community. Delays
should be reduced for good control of tuberculo-
sis. Education of physicians and the public about
tuberculosis, reductions in healthcare system and
laboratory delays, together with improvements in
economic status and sociocultural factors, are the
most important factors likely to reduce delays in
diagnosis and treatment among tuberculosis
patients.
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ABSTRACT
Vancomycin serum concentrations were deter-
mined for 1737 patients treated with either 2 · 1
g of vancomycin or 4 · 500 mg daily (780 pa-
tients), according to current nomograms, or by
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